Before the introduction of antipsychotics, links between schizophrenia and abnormal glucose metabolism levels were found in the late 1800s as an increased prevalence of diabetes in families with a history of "insanity."
1 Furthermore, it is known that some patients with psychosis require higher dosages than other patients when applying insulin therapy, suggestive of insulin resistance. 2 A recent meta-analysis by Pillinger et al 1 assessed
insulin resistance and found an elevated homeostatic model assessment of insulin resistance (HOMA-IR) among drug-naive patients with first-episode schizophrenia (n = 560) compared with controls (n = 450). 1 They highlighted hormonal stress axis activation and lifestyle factors as potential confounders. 1 Stress hormones, such as cortisol and catecholamines, are catabolic and functional antagonists of insulin. Antipsychotic-naive individuals with first-episode psychosis exhibit higher baseline cortisol levels and a blunted cortisol awakening response compared with controls. 1, 3 To test whether insulin resistance in schizophrenia can be discerned from stress-related and medication effects, we assessed HOMA-IR and stress hormone levels among drug-naive patients with first-episode schizophrenia and matched controls.
Methods | Morning urine and blood samples (taken at 8 AM after the patients fasted) were obtained from 24 acute, drugnaive patients with first-episode schizophrenia and 24 controls. All participants were white and matched for sex, age, body mass index (BMI) (calculated as weight in kilograms divided by height in meters squared), and waist-hip ratio ( analysis of covariance using an aligned rank transformation of the data (http://www.r-project.org) was performed to control for the diagnostic group effects regarding HOMA-IR for the covariates BMI, waist-hip ratio, cortisol levels, metanephrine levels, normetanephrine levels, and smoking. 71.5 [42.9-127 .1]; P = .03) and normetanephrine (median [IQR], ; P = .08) levels increased approximately 1.7-fold and 1.5-fold, respectively, although only the latter trended toward significance (P < .10). Homeostatic model assessment of insulin resistance was correlated with BMI (r = 0.463;P = .001), but no significant correlations were found between HOMA-IR and levels of cortisol (r = 0.097; P = .52), metanephrine (r = 0.123; P = .41), normetanephrine (r = 0.161; P = .28) or smoking (r = 0.094; P = .53) ( Table 2) . Homeostatic model assessment of insulin resistance was not related to PANSS-P (r = 0.086; P = .69), PANSS-N (r = 0.099; P = .65), PANSS-G (r = −0.183; P = .39), or PANSS sum (r = 0; P = .99). Additional testing showed that the schizophrenia-related HOMA-IR increase was present among nonsmokers (patients: n = 8, controls: n = 18; P = .02). The diagnostic group difference regarding HOMA-IR was confirmed by an analysis of covariance using an aligned rank transformation (F = 10.172, P = .003). Only the covariate BMI had significant influence in this model (patients: median [IQR], ; controls: median [IQR], ]; F = 9.001, P = .005).
Discussion | We found that although serum and urinary stress hormone levels were increased in acute psychosis; this was not related to HOMA-IR. Notably, glucose metabolism is regulated redundantly and may be impaired by stress or biological insults in many ways (eg, central sympathetic control through multiple neurotransmitters). The patient and control groups were well-matched for sex, age, BMI, and waisthip ratio to rule out the possibility that being overweight and visceral adiposity could be factors that explained increased HOMA-IR scores among patients. While the lifestyle factors "exercise," "sedentary behavior," and "diet" were not examined in this study, HOMA-IR was not related to smoking.
These results support the recently raised notion of impaired insulin/glucose homeostasis in drug-naive patients with first-episode schizophrenia, small sample and effect sizes notwithstanding. 1, 6 Reduced insulin sensitivity may arise independently from pharmacotherapy, hormonal stress axis activation, or obesity. 6 Glucose metabolism levels should be assessed in larger samples and other psychiatric disorders to examine specificity for schizophrenia. 
COMMENT & RESPONSE

Ketamine for the Treatment of Depression
To the Editor We congratulate Sanacora et al 1 for the publication of their consensus statement in JAMA Psychiatry. The growing amount of literature on this topic has generated interest among patients and physicians, which called for such an important document as the basis for decision-making societies, health care professionals, and regulatory authorities. Until official approval of depression as an indication, offlabel uses by medical experts assuming legal, scientific, and medical hazards will increase. On the other hand, ketamine clinics or ketamine wellness centers already offer ketamine as outpatient treatment with unscientific and dangerous methods. To overcome the lack of regulation, consensus statements and their dissemination are of utmost importance. Off-label administration of psychopharmaceuticals is very common in adult psychiatric practice, eg, quetiapine as an augmentative antidepressant, and pivotal in child and adolescent psychiatry. A previous study in the United States estimated that around 21% of all prescriptions in 2001 were off-label, with the highest rates for anticonvulsants (74%), antipsychotics (60%), and antibiotics (41%).
2 Furthermore, figures showed that a substantial amount of off-label prescriptions (73%) lacked scientific support. Indeed, recommendations on off-label use have suggested that evaluation of evidence to justify an off-label use is of utmost importance for prescribers, and justification of offlabel prescriptions is strongest when rigorous research supports it. 3 While existing studies and this consensus statement on ketamine in treatment-resistant major depression warrant ethical standards in off-label treatment as far as short-term improvements are concerned, long-term use data on preventing relapses are missing. Hence, the suggestion by Sanacora et al 1 to discontinue ketamine based on lack of efficacy is crucial. Moreover, current literature is scarce in conditions other than major depression, so thorough patient evaluation is indispensable. Hence, close psychiatric examination and evaluation contradict ketamine administration by nonpsychiatric specialists. An ethical and legal framework for off-label use in the European Union shows that demonstration of a "careful physician," eg, in a courtroom, is crucial to avoid medical malpractice. 4 This includes standards in patient information and informed consent. Although explaining ketamine treatment to patients with acute depression might be a complicated task, ethical and legal standards demand informed consent, which is well acknowledged in the preprocedural evaluation table in the article. 1 We recently published an informed consent form available for clinical use. 5 This might further promote high standards in antidepressant ketamine treatment and avoid clinical errors, which could be a potential setback to propagation of a beneficial treatment for treatment-resistant patients.
